Diaceutics, a Belfast-based tech company serving the pharmaceutical industry, received a £1 million grant from the U.K. Research Institute’s Strength in Places Fund. The company provides pharma and biotech organizations with tools for launching precision medicine diagnostics.
“We are very grateful to the UKRI for awarding this funding, which we will deploy to support our R&D activities,” Ryan Keeling, Diaceutics’ CEO, said in a statement. “Initiatives such as this are very important and will help us progress our data products, clinical data and bioinformatics pipeline development, staff skills and apprenticeships development.”
Diaceutics operates a diagnostic commercialization platform that integrates multiple pipelines of real-world diagnostic testing data from a global network of laboratories. Through Diaceutics’ marketing platform, this network enables stakeholders to collaborate on solving real-world testing challenges, offering them a secure and standardized method of using precision medicine diagnostics.
The grant money will help Diaceutics identify opportunities for improvement in clinical practices that will enable patients in Northern Ireland and across the U.K. to benefit from precision medicine. Diaceutics will invest in enhancing its data products in 2025.
